Stem cells take on ankylosing spondylitis: first human trial begins

NCT ID NCT07632599

Not yet recruiting Disease control Sponsor: Eighth Affiliated Hospital, Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether stem cells from donated bone marrow (CG-BM1) are safe for people with ankylosing spondylitis, a chronic inflammatory arthritis. Forty adults aged 18 to 40 will receive either the stem cells or a placebo by IV once a week for four weeks. The study will monitor side effects and look for signs of improvement in pain, stiffness, and function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: allogeneic human bone marrow mesenchymal stem cells (CG-BM1)
What this could lead to: If successful, this could point toward a new treatment option for ankylosing spondylitis that reduces inflammation and improves symptoms.
What could go wrong: This is a very early Phase 1 trial with only 40 participants, so safety and effectiveness are not yet proven. The stem cells may cause side effects or not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ankylosing spondylitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANKYLOSING SPONDYLITIS

Contacts and locations

Show contact details

Locations

The Eighth Affiliated Hospital, Sun Yat-sen University

Shenzhen, Guangdong, 518033, China

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.